Further, Park et al (2001) indicated that metastatic colorectal cancer patients with the wild-type XPD genotype respond to 5-fluorouracil/oxaliplatin and have longer median survival vs those with the variant genotypes. The gene discussed is ERCC2; the disease is metastatic colorectal cancer.